Cite
MLA Citation
Carla Boquimpani et al.. “Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib.” Leukemia & lymphoma, vol. 56, no. 6, n.d., pp. 1787–1792. http://access.bl.uk/ark:/81055/vdc_100026017630.0x000020